La Jolla reports additional Phase III data for LJPC-501 in catecholamine-resistant hypotension

In September, La Jolla Pharmaceutical Co. (NASDAQ:LJPC) reported additional data from the Phase III ATHOS-3 trial of LJPC-501 (angiotensin II) to treat hypotension in

Read the full 245 word article

User Sign In